Literature DB >> 26991959

Increased microcirculation detected by dynamic contrast-enhanced magnetic resonance imaging is of prognostic significance in asymptomatic myeloma.

Jens Hillengass1,2, Judith Ritsch2, Maximilian Merz1,2, Barbara Wagner1, Christina Kunz3, Thomas Hielscher3, Hendrik Laue4, Tobias Bäuerle5, Christian M Zechmann6, Anthony D Ho1, Heinz-Peter Schlemmer2, Hartmut Goldschmidt1,7, Thomas M Moehler8, Stefan Delorme2.   

Abstract

This prospective study aimed to investigate the prognostic significance of dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) as a non-invasive imaging technique delivering the quantitative parameters amplitude A (reflecting blood volume) and exchange rate constant kep (reflecting vascular permeability) in patients with asymptomatic monoclonal plasma cell diseases. We analysed DCE-MRI parameters in 33 healthy controls and 148 patients with monoclonal gammopathy of undetermined significance (MGUS) or smouldering multiple myeloma (SMM) according to the 2003 IMWG guidelines. All individuals underwent standardized DCE-MRI of the lumbar spine. Regions of interest were drawn manually on T1-weighted images encompassing the bone marrow of each of the 5 lumbar vertebrae sparing the vertebral vessel. Prognostic significance for median of amplitude A (univariate: P < 0·001, hazard ratio (HR) 2·42, multivariate P = 0·02, HR 2·7) and exchange rate constant kep (univariate P = 0·03, HR 1·92, multivariate P = 0·46, HR 1·5) for time to progression of 79 patients with SMM was found. Patients with amplitude A above the optimal cut-off point of 0·89 arbitrary units had a 2-year progression rate into symptomatic disease of 80%. In conclusion, DCE-MRI parameters are of prognostic significance for time to progression in patients with SMM but not in individuals with MGUS.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  Smouldering multiple myeloma; dynamic contrast-enhanced magnetic resonance imaging; monoclonal gammopathy of undetermined significance; prognosis; risk factor

Mesh:

Year:  2016        PMID: 26991959     DOI: 10.1111/bjh.14038

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  10 in total

Review 1.  Whole-body MRI, dynamic contrast-enhanced MRI, and diffusion-weighted imaging for the staging of multiple myeloma.

Authors:  Julie C Dutoit; Koenraad L Verstraete
Journal:  Skeletal Radiol       Date:  2017-03-13       Impact factor: 2.199

Review 2.  Bone marrow MR perfusion imaging and potential for tumor evaluation.

Authors:  James F Griffith; R A van der Heijden
Journal:  Skeletal Radiol       Date:  2022-10-22       Impact factor: 2.128

Review 3.  Functional and molecular MRI of the bone marrow in multiple myeloma.

Authors:  Vassilis Koutoulidis; Nickolas Papanikolaou; Lia A Moulopoulos
Journal:  Br J Radiol       Date:  2018-02-13       Impact factor: 3.039

Review 4.  Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease.

Authors:  Johannes M Waldschmidt; Praveen Anand; Birgit Knoechel; Jens G Lohr
Journal:  Semin Hematol       Date:  2018-03-01       Impact factor: 3.851

5.  Dynamic contrast-enhanced MRI for the assessment of spinal tumor vascularity: correlation with angiography.

Authors:  Xiao-Xi Meng; Yong-Qiu Zhang; Hua-Qiang Liao; Hong-Chao Liu; Hai-Lin Jiang; Shu-Jun Ke; Wei-Hua Dong
Journal:  Eur Spine J       Date:  2016-07-23       Impact factor: 3.134

Review 6.  [Hemato-oncological imaging : Importance of hybrid procedures].

Authors:  M E Mayerhoefer; A Haug
Journal:  Radiologe       Date:  2016-07       Impact factor: 0.635

Review 7.  MRI and PET/MRI in hematologic malignancies.

Authors:  Marius E Mayerhoefer; Stephen J Archibald; Christina Messiou; Anton Staudenherz; Dominik Berzaczy; Heiko Schöder
Journal:  J Magn Reson Imaging       Date:  2019-07-01       Impact factor: 4.813

8.  Volumetry based biomarker speed of growth: Quantifying the change of total tumor volume in whole-body magnetic resonance imaging over time improves risk stratification of smoldering multiple myeloma patients.

Authors:  Markus Wennmann; Laurent Kintzelé; Marie Piraud; Bjoern H Menze; Thomas Hielscher; Johannes Hofmanninger; Barbara Wagner; Hans-Ulrich Kauczor; Maximilian Merz; Jens Hillengass; Georg Langs; Marc-André Weber
Journal:  Oncotarget       Date:  2018-05-18

9.  Cancer Stem Cell Marker DCLK1 Correlates with Tumorigenic Immune Infiltrates in the Colon and Gastric Adenocarcinoma Microenvironments.

Authors:  Xiangyan Wu; Dongfeng Qu; Nathaniel Weygant; Jun Peng; Courtney W Houchen
Journal:  Cancers (Basel)       Date:  2020-01-22       Impact factor: 6.639

Review 10.  Whole-body magnetic resonance imaging (WBMRI) versus whole-body computed tomography (WBCT) for myeloma imaging and staging.

Authors:  Karla M Treitl; Jens Ricke; Andrea Baur-Melnyk
Journal:  Skeletal Radiol       Date:  2021-05-24       Impact factor: 2.199

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.